CLINICAL TRIALS AND OBSERVATIONS Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo–purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group

نویسندگان

  • Christian H. Geisler
  • Arne Kolstad
  • Anna Laurell
  • Niels S. Andersen
  • Lone B. Pedersen
  • Mats Jerkeman
  • Mikael Eriksson
  • Marie Nordström
  • Eva Kimby
  • Anne Marie Boesen
  • Outi Kuittinen
  • Grete F. Lauritzsen
  • Herman Nilsson-Ehle
  • Elisabeth Ralfkiær
  • Måns Åkerman
  • Mats Ehinger
  • Christer Sundström
  • Ruth Langholm
  • Jan Delabie
  • Peter Brown
چکیده

Christian H. Geisler,1 Arne Kolstad,2 Anna Laurell,3 Niels S. Andersen,1 Lone B. Pedersen,1 Mats Jerkeman,4 Mikael Eriksson,4 Marie Nordström,5 Eva Kimby,5 Anne Marie Boesen,6 Outi Kuittinen,7 Grete F. Lauritzsen,2 Herman Nilsson-Ehle,8 Elisabeth Ralfkiær,1 Måns Åkerman,4 Mats Ehinger,4 Christer Sundström,3 Ruth Langholm,2 Jan Delabie,2 Marja-Liisa Karjalainen-Lindsberg,9 Peter Brown,1 and Erkki Elonen9 for the Nordic Lymphoma Group

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

CLINICAL TRIALS AND OBSERVATIONS The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma

Given the significant activity and tolerability of bendamustine, rituximab, and bortezomib in patients with relapsed indolent and mantle cell non-Hodgkin lymphoma, and laboratory studies suggesting synergistic activity, we conducted a multicenter phase 2 study of the bendamustine/ bortezomib/rituximab combination. Patients with relapsed or refractory indolent and mantle cell lymphoma with adequ...

متن کامل

CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network

Mantle-cell lymphoma (MCL) is characterized by poor prognosis with a median survival of only 3 to 4 years. To improve clinical outcome, the European MCL Network initiated a randomized trial comparing consolidation with myeloablative radiochemotherapy followed by autologous stem cell transplantation (ASCT) to interferon maintenance (IFN ) in first remission. Patients 65 years of age or younger w...

متن کامل

CLINICAL TRIALS AND OBSERVATIONS Standard chemotherapy with interferon compared with CHOP followed by high-dose therapy with autologous stem cell transplantation in untreated patients with advanced follicular lymphoma: the GELF-94 randomized study from the Groupe d’Etude des Lymphomes de l’Adulte (GELA)

The purpose of this study is to compare our standard chemotherapy regimen (CHVP [cyclophosphamide, doxorubicin, teniposide, and prednisone]) plus interferon with 4 courses of CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) followed by high-dose therapy with autologous stem cell transplantation (ASCT) in treatment-naive patients with advanced follicular lymphoma. Four hundred o...

متن کامل

CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Age-adjusted International Prognostic Index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma

Second-line chemotherapy followed by high-dose therapy (HDT) with autologous stem cell transplantation (ASCT) cures less than half of the patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). Prognostic models capable of predicting outcome are essential. In 3 sequential clinical trials, conducted from January 1993 to August 2000, we treated 150 patients with relapsed or pr...

متن کامل

CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma

We report the outcomes after reducedintensity conditioning allogeneic stem cell transplantation (RIT) for non-Hodgkin lymphoma (NHL) in 88 patients (low-grade NHL [LG-NHL], n 41; high-grade NHL [HG-NHL], n 37; mantle cell lymphoma [MCL], n 10). Thirty-seven patients had previously received autografts, and 21 were in complete remission (CR) at transplantation. Conditioning therapy consisted of a...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:

دوره   شماره 

صفحات  -

تاریخ انتشار 2008